Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 1:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 16,814 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Symptom Clusters Clear all
Completed Not applicable Interventional

Auditory Neural Function in Implanted Patients With Usher Syndrome

NCT04906135
View directory record Official record
Conditions
Usher Syndrome, Cochlear Implantation
Interventions
Experimental manipulation of stimulation parameters
Other
Lead sponsor
Ohio State University
Other
Eligibility
1 Year to 85 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Boston, Massachusetts • Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 2 Interventional

Subgroups of Fibromyalgia Syndrome (FMS): Symptoms, Beliefs, and Tailored Treatment

NCT00762125
View directory record Official record
Conditions
Fibromyalgia
Interventions
CR+ST, ET, AC treatment
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 3 Interventional

A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients

NCT00046176
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions
abacavir/lamivudine, abacavir, lamivudine
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
52
States / cities
Phoenix, Arizona • Fountain Valley, California • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 2 Interventional

Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia

NCT00003868
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, methotrexate, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, iodine I 131 monoclonal antibody BC8, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
2 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 24, 2010 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Not applicable Interventional

SOFI: A Quality Improvement Project to Standardize Use of Intravenous Fluids in Hospitalized Pediatric Patients

NCT03924674
View directory record Official record
Conditions
Intravenous Fluids, Fluid and Electrolyte Imbalance, ADH Inappropriate
Interventions
Education, clinical decision support tools
Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
28 Days to 18 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
89
States / cities
Phoenix, Arizona • Fresno, California • Loma Linda, California + 76 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Oct 24, 2026, 1:38 PM EDT
Recruiting Not applicable Interventional

Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection

NCT05219110
View directory record Official record
Conditions
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Interventions
Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
Other
Lead sponsor
University of Calgary
Other
Eligibility
9 Months to 21 Years
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 4 Interventional Results available

Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)

NCT00805935
View directory record Official record
Conditions
Polycystic Ovarian Syndrome, Infertility
Interventions
Menotropin, Progesterone vaginal insert, Follitropin beta, Progesterone in oil, leuprolide acetate
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 42 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Littleton, Colorado • Clearwater, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2012 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 1 Interventional Results available

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

NCT00513474
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
busulfan, cyclophosphamide, cyclosporin-A, etoposide, methotrexate, rasburicase, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation, fludarabine, allopurinol
Drug · Procedure · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 24, 2026, 1:38 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of Adrenal Androgens in Normal and Obese Girls After Suppression and Stimulation

NCT01421797
View directory record Official record
Conditions
Hyperandrogenemia, Polycystic Ovary Syndrome, Obesity
Interventions
Dexamethasone, Cortrosyn
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 24, 2026, 1:38 PM EDT
Terminated Phase 1 Interventional

Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant

NCT02846376
View directory record Official record
Conditions
Acute Myeloid Leukemia and Myelodysplastic Syndrome
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 2Phase 3 Interventional

The ATLAST Long-Term Study

NCT01476917
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
Attune Sleep Apnea System
Device
Lead sponsor
ApniCure, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Phoenix, Arizona • Burlingame, California • Menlo Park, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 24, 2026, 1:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Women's HIV SeroIncidence Study (ISIS)

NCT00995176
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
18 Years and older
Enrollment
2,099 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Decatur, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 1Phase 2 Interventional

Cholesterol in ASD: Characterization and Treatment

NCT00965068
View directory record Official record
Conditions
Autism, Asperger Disorder, PDD-NOS
Interventions
Cholesterol
Other
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
4 Years to 12 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 24, 2026, 1:38 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating the Effectiveness of a Mobile HIV Prevention App to Increase HIV and Sexually Transmitted Infections (STI) Testing and PrEP Initiation Among Rural Men Who Have Sex With Men

NCT06205368
View directory record Official record
Conditions
HIV Infections, STI, HIV Pre-exposure Prophylaxis
Interventions
Combine mobile app, Motivational interview, HIV/STI testing
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
473 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

HIV Testing Strategies in the Perinatal Setting

NCT00503308
View directory record Official record
Conditions
HIV Infections, Pregnancy Related
Interventions
Abbreviated HIV test counseling
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years and older · Female only
Enrollment
281 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 22, 2015 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Comparison of Eleview Versus Hetastarch as Injectate for EMR

NCT03350217
View directory record Official record
Conditions
Procedural Bleeding, Delayed Bleeding, Post-Polypectomy Syndrome, Post Procedural Complication
Interventions
Eleview, Hetastarch
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 24, 2026, 1:38 PM EDT
Completed No phase listed Observational

Incidence of Malignant Peripheral Nerve Sheath Tumor (MPNST) Development in Participants With Neurofibromatosis Type 1 (NF1) Receiving and Not Receiving Medical Therapies Directed at Plexiform Neurofibromas (PN)

NCT04774289
View directory record Official record
Conditions
Neurofibromatosis 1, Peripheral Nerve Neoplasms, Malignant
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Month and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome

NCT02738450
View directory record Official record
Conditions
Down Syndrome
Interventions
ACI-24 low dose, ACI-24 high dose, Placebo
Biological
Lead sponsor
AC Immune SA
Industry
Eligibility
25 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Phoenix, Arizona • La Jolla, California • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Not applicable Interventional

A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients

NCT00002050
View directory record Official record
Conditions
HIV Infections
Interventions
Thymopentin
Drug
Lead sponsor
Immunobiology Research Institute
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Annandale, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 24, 2026, 1:38 PM EDT
Completed No phase listed Observational

Retrospective Chart Review of Subcutaneous IgG Use in Infants

NCT01166074
View directory record Official record
Conditions
Primary Immune Deficiency
Interventions
Subcutaneous IgG (SCIG)
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
Up to 2 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
5
States / cities
Los Angeles, California • Tampa, Florida • Plymouth, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2011 · Synced Oct 24, 2026, 1:38 PM EDT
Terminated No phase listed Observational

Evaluation of Sleep Disordered Breathing Following Ambulatory Surgery

NCT01851798
View directory record Official record
Conditions
Sleep Disordered Breathing
Interventions
Home sleep test administered to all enrolled subjects
Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 85 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 24, 2026, 1:38 PM EDT
Recruiting Not applicable Interventional

taVNS for FRNS in Children

NCT05588063
View directory record Official record
Conditions
Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
Interventions
Transcutaneous auricular vagus nerve stimulation, Sham device
Device
Lead sponsor
Northwell Health
Other
Eligibility
3 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New Hyde Park, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 24, 2026, 1:38 PM EDT
Recruiting Phase 4 Interventional

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

NCT07228221
View directory record Official record
Conditions
Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions
iStent infinite trabecular micro-bypass system model iS3, iDose TR (Travoprost intracameral Implant) 75mcg
Device · Drug
Lead sponsor
Jonathon Myers
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine

NCT00098293
View directory record Official record
Conditions
HIV-1
Interventions
Maraviroc + Zidovudine/Lamivudine, Efavirenz + Zidovudine/Lamivudine, Maraviroc (UK-427,857) + Zidovudine/Lamivudine
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
916 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
46
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Oct 24, 2026, 1:38 PM EDT